Showing 2081-2090 of 2530 results for "".
- Alastin Skincare's INhance Post-Injection Serum Speeds Recoveryhttps://modernaesthetics.com/news/alastin-skincares-inhance-post-injection-serum-speeds-recovery/2472951/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in
- ASPS: Many Americans Look Forward to Plastic Surgery in Post COVID-19 Worldhttps://modernaesthetics.com/news/asps-many-americans-look-forward-to-plastic-surgery-in-post-covid-19-world/2472948/Americans report a positive attitude about plastic surgery even during the COVID-19 pandemic, according to a new survey from the American Society of Plastic Surgery. In the survey of more than 1,000 consumers who were polled during the pandemic, 49 percent of those who haven't had p
- RealSelf Medical Advisory Board Adds Plastic Surgeon Dr. Arian Mowlavihttps://modernaesthetics.com/news/realself-medical-advisory-board-adds-newport-beach-plastic-surgeon-dr-arian-mowlavi/2472947/Newport Beach, Calif.-based plastic surgeon Arian Mowlavi, MD is now a member of RealSelf’s Medical Advisory Board. “RealSelf is a leader in plastic surgery patient education and I am proud to a member of their Medical Advisory Board,” says Dr. Mowlavi of Cosmetic Plas
- Meet Cynosure’s Upgraded Elite iQ Aesthetic Workstationhttps://modernaesthetics.com/news/meet-cynosures-upgraded-elite-iq-aesthetic-workstation/2472944/Cynosure is launching the Elite iQ platform – the next generation of Cynosure’s Elite+ Aesthetic Workstation and the first Alexandrite-ND: YAG System to U.S., European and Australian mark
- Aesthetic Practices Weigh Pros and Cons of COVID-19 Testing Patients and Staff as Part of Reopening Planshttps://modernaesthetics.com/news/aesthetic-practices-weigh-pros-and-cons-of-covid-19-testing-patients-and-staff-as-part-of-reopening-plans/2472938/COVID-19 antibody testing can play an important role in identifying people who have recovered from the SARS-CoV-2 virus and who have high levels of antibodies in their blood that could potentially help other critically ill COVID-19 patients. The presence of antibodies may also suggest immuni
- Pilot Study Demonstrates Benefits of Topical NO Serum for Aging Skinhttps://modernaesthetics.com/news/pilot-study-demonstrates-benefits-of-topical-no-serum-for-aging-skin-1/2472934/A patent-pending topical Nitric Oxide serum may boost circulation and pro-fibroblastic-enhancing capabilities when used alone and improve absorption dynamics when combined with other products, according to a
- Cutera Looks to Honor COVID-19 Championshttps://modernaesthetics.com/news/cutera-looks-to-honor-covid-19-champions/2472929/From physicians going back to the ER and conducting hospital rounds to supporting food depositories and shelters, to doctors donating personal protective equipment, ventilators, and office facilities as needed during the COVID-19 global pandemic, Cutera wants to shine a spotlight on its customers
- FDA Clears Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting Systemhttps://modernaesthetics.com/news/fda-clears-bimini-health-techs-dermapose-access-office-based-fat-harvesting-system/2472922/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access system creates a new pr
- Lumenis Virtual Conference 2020 Starts Tomorrowhttps://modernaesthetics.com/news/lumenis-virtual-conference-2020-starts-tomorrow/2472918/Those interested in learning more about the latest laser and RF technologies, seeking treatment tips, or looking to network with other practitioners may be interested in the Lumenis Virtual Conference 2020. The conference kicks off Thursday, April 23 and Friday, April 24 with live
- Cutera Closes Public Stock Offeringhttps://modernaesthetics.com/news/cutera-closes-public-stock-offering/2472917/Cutera, Inc. has closed its previously announced underwritten public offering of 2,742,750 shares of its common stock at a public offering price of $10.50 per share, which includes the exercise in full of the underwriter’s option to purchase up to an additional 357,750 shares of its co